STAT February 23, 2018
Health care luminaries met to discuss the promise of precision medicineat a panel in Davos last month. As is typical for discussions at the World Economic Forum, the participants explored big issues — global diversity, artificial intelligence, and the ethical complexities of modern medicine.
Hearing these leaders assess the potential of data-driven medicine, I was struck by a simple fact: Mundane and subtle obstacles like insurance models, legacy processes, and siloed data are defining the on-the-ground reality for precision medicine. All of those are issues that community providers are well-positioned to address.
The science of precision medicine is already here: There are currently tens of thousands of commercially available genetic and genomic tests, plus more than 300 FDA-approved drugs tied...
Today's Sponsors
Today's Sponsor